Clinical Trial: An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06961344) titled 'An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)' on April 28.

Brief Summary: The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed the lead-in study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study at the daily dose of 15mg. The study medication is a once daily oral table and will be provided at the clinic and/or shipped to the participant's home. Study assessments will be conducted during clinic visits which will occur at three months and then at six months. Thereafter, clinic vi...